Ticagrelor + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Abdominal Aortic Aneurysm

Conditions

Abdominal Aortic Aneurysm

Trial Timeline

Mar 1, 2014 → Jul 1, 2017

NCT ID

NCT02070653

About Ticagrelor + Placebo

Ticagrelor + Placebo is a phase 2 stage product being developed by AstraZeneca for Abdominal Aortic Aneurysm. The current trial status is completed. This product is registered under clinical trial identifier NCT02070653. Target conditions include Abdominal Aortic Aneurysm.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03615924	Phase 3	Terminated	Sep 26, 2018	Aug 13, 2020	Sickle Cell Disease
NCT03354429	Phase 3	Completed	Jan 22, 2018	Dec 13, 2019	Acute Ischaemic Stroke
NCT02482298	Phase 2	Completed	Jul 9, 2015	Nov 16, 2016	Sickle Cell Disease
NCT02352402	Phase 3	UNKNOWN	Mar 1, 2015	Aug 1, 2020	Coronary Artery Disease
NCT02110303	Phase 2/3	Completed	Mar 1, 2015	Apr 1, 2018	Coronary Artery Disease
NCT02335099	Phase 1/2	Completed	Dec 1, 2014	Jun 1, 2019	End Stage Renal Disease
NCT01998399	Phase 2	Terminated	Aug 1, 2014	Dec 1, 2015	Community Acquired Pneumonia, Severe
NCT02070653	Phase 2	Completed	Mar 1, 2014	Jul 1, 2017	Abdominal Aortic Aneurysm
NCT01347580	Approved	Completed	Sep 1, 2011	Nov 1, 2013	Myocardial Infarction

Competing Products

20 competing products in Abdominal Aortic Aneurysm

See all competitors

Product	Company	Stage	Hype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tablets	Jiangsu Hengrui Medicine	Phase 3	77
HR021618 + Placebo	Jiangsu Hengrui Medicine	Phase 2	52
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	77
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg	Merck	Phase 3	77
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	77
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	77
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	52
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet	Merck	Phase 2/3	65
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 Weeks	Merck	Phase 3	77
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	77
LYS228 + Standard of care therapy	Novartis	Phase 2	52
ACZ885 + Placebo	Novartis	Phase 2	52
Evolocumab + Placebo	Amgen	Phase 1	32
tigecycline	Pfizer	Phase 3	76
recombinant human growth hormone	Pfizer	Phase 3	76
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalin	Pfizer	Approved	84
Ceftazidime-avibactam + metronidazole + Meropenem	Pfizer	Phase 3	76

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved